Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 601–700 of 796
Management of autoimmune and viral hepatitis in immunotherapy: a narrative review
Kuo, L., Kuwelker, S., & Tsai, E. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-23-250 · Cited by 6
Kumar, V., Raghuvanshi, S., Bhalla, S., Rawat, S., Ojha, B. K., Srivastava, C., & Goel, M. (2025) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2405_23 · Cited by 6
Cancer immunotherapy by targeting immune checkpoint receptors
Isakov, N. (2018) · World Journal of Immunology · doi:10.5411/wji.v8.i1.1 · Cited by 6
Lai, L., Zhan, Z., Feng, M., Li, F., Lai, L.-F., & Lu-xing, Z. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000921 · Cited by 6
Research progress of PD‐L1 non‐glycosylation in cancer immunotherapy
Cao, P., Yang, X., Liu, D., Ye, S., Yang, W. Y., Xie, Z., & Lei, X. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13205 · Cited by 6
Bai, J., Huang, J., Ye, Y., Lin, J., Wen, Y., Cai, Z., Chen, P., Shangguan, T., Zou, G., Qiu, Q., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14562-6 · Cited by 6
Vasudev, N. S., & Banks, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803014-1.00009-1 · Cited by 6
Lopes, M. L. D. D. S., Liu, Y., Liu, K. Y.-P., da Silveira, É. J. D., & Poh, C. F.-Y. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.07.017 · Cited by 6
Zhou, Q., Sun, E., Ling, L., Liu, X., Zhang, M., Yin, H. X., & Lu, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6947 · Cited by 6
Tao, J., Dai, J., & Hou, S. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5100 · Cited by 6
Wang, J., Sun, M., Zhu, X., Zhao, H., Mao, D., Zhang, Z., & Zhao, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10426 · Cited by 10
Combination of pembrolizumab and 125I attenuates the aggressiveness of non‑small cell lung cancer
Wang, S., Zhang, J., Meng, F., Yan, Y., Wang, B., & Guan, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11508 · Cited by 6
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series
Fernández‐Trujillo, L., García-Robledo, J. E., Zúñiga-Restrepo, V., & Sua, L. F. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101114 · Cited by 6
Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression
Whiteside, T. L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6750-1_1 · Cited by 6
Chen, J., Li, H., Pang, R., & Huang, J. M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s127498 · Cited by 5
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Yamada, S., Itai, S., Kaneko, M. K., & Kato, Y. (2018) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.01.009 · Cited by 5
Jiang, W., Wang, D., Liu, X., Zheng, W., Wen, L., Shi, H., Zhang, H., Zhou, A., Li, C., Ma, J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.09.012 · Cited by 5
Tamada, S., Nozawa, M., Ohba, K., Mizuno, R., Takamoto, A., Ohe, C., Yoshimoto, T., Nakagawa, Y., Fukuyama, T., Matsubara, N., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02256-z · Cited by 5
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
Uemura, M., Nakaigawa, N., Sassa, N., Tatsugami, K., Harada, K., Yamasaki, T., Matsubara, N., Yoshimoto, T., Nakagawa, Y., Fukuyama, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01993-x · Cited by 5
Liu, X., Liu, X., Zhang, H., Wang, C., Li, Z., Zhu, Q., Feng, Y., Fan, J., Qi, S., & Wu, Z. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230511123157 · Cited by 6
Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation
Pen, J. J., Aerts, J. L., Liechtenstein, T., Escors, D., & Breckpot, K. (2014) · InTech eBooks · doi:10.5772/57539 · Cited by 6
Ghapanchi, J., Ghaderi, H., Haghshenas, M. R., Jamshidi, S., Rezazadeh, F., Azad, A., Farzin, M., Derafshi, R., & Kalantari, A. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.2.421 · Cited by 5
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Digifico, E., Belgiovine, C., Mantovani, A., & Allavena, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_5 · Cited by 6
Kim, J. K., Kim, S., Shin, E., Jung, J., Choi, H., & Jun, K. (2019) · PubMed Central · doi:10.3892/ol.2019.10594 · Cited by 5
Yuan, G., Hu, X., Li, Q., Dai, W., Cheng, X., Ying, P., Yu, W., Guo, Y., Chen, M., & Chen, J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14452 · Cited by 5
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)
Atkins, M. B., & Philips, G. K. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1226798 · Cited by 5
Prognostic Factors for Localized Renal Cell Carcinoma
Lane, B. R. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-062-5_5 · Cited by 6
Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma
Kaplan, Z., Prezioso, E., Jain, A., Lavu, H., Yeo, C. J., Bowne, W. B., & Nevler, A. (2025) · Cancer Medicine · doi:10.1002/cam4.70960 · Cited by 4
Immune-checkpoint inhibitor resistance in patients with cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 6
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
Maia, M. C., Dizman, N., Salgia, M. M., & Pal, S. K. (2017) · Kidney Cancer · doi:10.3233/kca-170006 · Cited by 4
Hamed, M., Gouida, M. S. O., EL-Aziz, S. R. A., & El-Sokkary, A. M. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09474 · Cited by 4
Nivolumab in renal cell carcinoma
Ortega, R. M. M., & Drabkin, H. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1049596 · Cited by 4
Nahas, G. R., Walker, N. D., Bryan, M., & Rameshwar, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29425 · Cited by 5
B7-H Abnormalities in Melanoma and Clinical Relevance
Seliger, B. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_19 · Cited by 4
Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma
von Klot, C. A. J., Merseburger, A. S., & Kuczyk, M. A. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.856 · Cited by 4
Immunosuppressive peculiarities of stromal cells of various kidney tumor types
Kovaleva, O. V., Rashidova, M. A., Samoilova, D. V., Алексеевна, П. П., Tabiev, R. M., Kuncevich, N. V., Efremov, G. D., Alekseev, B. Y., & Gratchev, A. N. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-2-29-35 · Cited by 4
Karakuş, F., Kuzu, B., Köstekci, S., & Tülüce, Y. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099307259240522093710 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Cytokine therapy for renal cell cancer: the evolving role of immunomodulation
Leary, A. F., Larkin, J., & Pickering, L. M. (2011) · Therapy · doi:10.2217/thy.11.26 · Cited by 4
Cancer Immunotherapy by Checkpoint Blockade
Minato, N., & Honjo, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00029-1 · Cited by 4
Jomrich, G., Kollmann, D., Wilfing, L., Radosavljevic, S., Ramazanova, D., Ristl, R., Grose, R. P., Ilhan‐Mutlu, A., Preusser, M., Fassnacht, C., et al. (2021) · European surgery. Supplement/European surgery · doi:10.1007/s10353-021-00700-4 · Cited by 5
Un tour d’horizon du développement de biomarqueurs pour les anticorps PD-1 et PD-L1 en cancérologie
Chaput, L., & Jordheim, L. P. (2021) · Therapies · doi:10.1016/j.therap.2021.06.005 · Cited by 4
Gene Editing: a Powerful Tool for Cancer Immunotherapy
(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac131.098 · Cited by 6
Pardoll, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00006-0 · Cited by 5
Vasudev, N. S., & Banks, R. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375672-5.10008-8 · Cited by 4
Gouw, L. G., Jones, K. B., Sharma, S., & Randall, R. L. (2011) · Cancers · doi:10.3390/cancers3044139 · Cited by 9
Jamil, M. L., Deebajah, M., Sood, A., & Alanee, S. R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027066 · Cited by 3
Tabriz, H. M., Nazar, E., Akhlaghi, N., & Javadi, A. E. (2022) · Nephro-Urology Monthly · doi:10.5812/numonthly-127476 · Cited by 3
Cancer Resistance to Immunotherapy
Khoury, R., Shayya, A., Orm, C. B., Deen, O. Z., & Ghanem, H. (2025) · Immuno · doi:10.3390/immuno5030032 · Cited by 3
Checkpoint Blockade Immunotherapy for Glioblastoma
Riccione, K. A., Gedeon, P. C., Sanchez-Perez, L., & Sampson, J. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00011-9 · Cited by 3
Jang, A., Sweeney, P. L., Barata, P. C., & Koshkin, V. S. (2021) · Kidney Cancer · doi:10.3233/kca-200108 · Cited by 3
YY1 expression and PD-1 regulation in CD8 T lymphocytes
Touboul, R., & Bonavida, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821909-6.00003-1 · Cited by 4
Habib, S., Azab, M. S., Elmasry, K., & Handoussa, A. E. (2021) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.315895 · Cited by 5
Oghalaie, A., Mahboudi, F., Jamnani, F. R., Piri‐Gavgani, S., Kazemi‐Lomedasht, F., Eskafi, A. H., Shahbazzadeh, D., Adeli, A., Talebkhan, Y., & Behdani, M. (2022) · PubMed Central · doi:10.22038/ijbms.2022.62522.13834 · Cited by 7
Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools
Cho, D., McDermott, D. F., & Atkins, M. B. (2006) · Current Urology Reports · doi:10.1007/s11934-006-0032-y · Cited by 3
Пили, Р., KAUFFMAN, E. C., & Rodríguez, R. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00082-5 · Cited by 3
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-22473-2_6 · Cited by 4
Progress and Potential of Immune Checkpoint Blockade for Treating Advanced Renal Cell Carcinoma
Tykodi, S. S. (2013) · Immunotherapy · doi:10.2217/imt.13.39 · Cited by 3
Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology
Andersen, M. H. (2014) · Immunologic Research · doi:10.1007/s12026-014-8559-3 · Cited by 6
Biomolecular prognostic factors in renal cell carcinoma: a literature review
Коган, М. И., Ахохов, З. М., Гусев, А. А., & Пасечник, Д. Г. (2016) · Cancer Urology · doi:10.17650/1726-9776-2016-12-3-45-51 · Cited by 4
The Multifaceted Role of PD-1 in Health and Disease
Badr, M. E. S. G., Hata, K., Furuhata, M., Toyota, H., & Yokosuka, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-56068-5_34 · Cited by 3
Systemische Immuncheckpoint-Inhibition: Eine vielversprechende Therapie urologischer Tumoren?
Urologie, F. M. U. D. A. U. F. (. D. D. G. F., Roos, F. C., Becker, C., Stope, M. B., & Tsaur, I. (2018) · Der Urologe · doi:10.1007/s00120-018-0622-6 · Cited by 3
Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report
Yamazoe, M., Tomioka, H., Kamada, T., Kaneko, M., & Katsuyama, E. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.11.011 · Cited by 3
The evolving role of immuno‐oncology for the treatment of head and neck cancer
Strome, A. L., Zhang, X., & Strome, S. E. (2019) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.235 · Cited by 4
Self-citationANALYSIS OF PROTEIN EXPRESSION OF PD-L1 IN MALIGNANT PLEURAL MESOTHELIOMA
Дмитриевна, К. Т., Козлов, Н. А., Lubchenko, L. N., Rotobelskaya, L. E., Багрова, С. Г., Сафронова, В. М., Лактионов, К. К., & Mb, B. (2018) · Russian Journal of Oncology · doi:10.18821/1028-9984-2018-23-1-4-9 · Cited by 3
Immunotherapy for Renal Cell Carcinoma
Qu, L., Wu, D., He, H., Xu, X., & Chen, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.77377 · Cited by 3
Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab
Shinder, B. M., Farber, N. J., Mayer, T. M., & Singer, E. A. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.04.013 · Cited by 2
Rajab, M. F., Shareef, A. A., Smail, S. W., Abdulqadir, S. Z., Jalal, K. F., Janson, C., Abdolmaleki, A., & Ghayour, M. B. (2025) · Cancer Management and Research · doi:10.2147/cmar.s560799 · Cited by 2
Tykocinski, M. L. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch30 · Cited by 2
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
Pardoll, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00052-4 · Cited by 3
Peng, Y., Li, Y., Lo, H. H., Law, B. Y. K., & Wong, V. K. W. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_6 · Cited by 2
Tajiri, K., 郁夫, 関., & 真樹, 家. (2019) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.28.0_3 · Cited by 2
Clinicopathological correlation and prognostic value of PD-L1 expression in renal cell carcinoma
Elkhodary, H. S., Nasr, K. E., Ahmed, S. H., Shakweer, M. M., & Ezz-Eldin, M. M. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.30329 · Cited by 2
Dostarlimab for Endometrial Cancer: A Comprehensive Review of Clinical Outcomes
Kanavi, R. S., Chathamvelli, A., & Saikia, D. (2023) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20230119 · Cited by 2
Deng, S., Zhang, P., Zeng, H., Wang, W., Jin, T., Wang, J., & Dong, Q. G. (2013) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2013.07.001 · Cited by 5
Immunosuppressive Microenvironment in Head and Neck Cancer
Lin, J., Lai, J., Biel, M. A., Xu, Y., & Chen, L. (2015) · InTech eBooks · doi:10.5772/60775 · Cited by 2
Self-citationRotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_12 · Cited by 2
Immunotherapy for Renal Cell Carcinoma
Davar, D., Fenton, M. J., & Appleman, L. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-062-5_16 · Cited by 2
Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies
Lipson, E. J., Taube, J. M., Chen, L., & Topalian, S. L. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_15 · Cited by 3
Self-citationYang, L., & Wu, Y.-L. L. C. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.80 · Cited by 2
de Freitas, A. M. S., Hartmann, A. A., & de Freitas, T. A. (2014) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.1590/s1676-24442014000100008 · Cited by 2
Association between B7-H1 expression and bladder cancer: a meta-analysis
Wang, Y., Liu, A. N. G., & Zhao, S. (2015) · Genetics and Molecular Research · doi:10.4238/2015.february.13.6 · Cited by 2
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
Marzolini, M. A. V., Quezada, S. A., & Peggs, K. S. (2015) · EMJ Oncology · doi:10.33590/emjoncol/10314057 · Cited by 3
Materials-Based Cancer Immunotherapies
Newton, J. M., Sikora, A. G., & Young, S. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00041-2 · Cited by 3
Schoon, J. J., Wood, S. L., & Brown, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00039-9 · Cited by 3
Nivolumab (Opdivo): Science-Based Antibody Drug, Which Opened a New Category of Cancer Treatments
Hara, Y., & Nagaoka, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-8906-1_14 · Cited by 2
Prognostic and predictive biomarkers for metastatic renal cell carcinoma
Briggs, L. G., Cone, E. B., Lee, R. J., & Blute, M. L. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.84 · Cited by 2
Self-citationMechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Moise, J., Murthy, J. J., Dabir, D., Yu, S., Kisto, F., Herron, E., & Aulakh, S. (2022) · Immuno · doi:10.3390/immuno2040041 · Cited by 2
Şahinli, H., Akyürek, N., Yılmaz, M., Kandemir, O., Duran, A. O., Kulaçoğlu, S., Uçar, G., Acar, E., Özet, A., Öksüzoğlu, B. Ç., et al. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_759_19 · Cited by 1
Katta, R., Thumma, R. R., Sai, P. D., & Padma, M. (2023) · Journal of Laboratory Physicians · doi:10.1055/s-0043-1771019 · Cited by 1
Prognostic Effectiveness of PD-L1 Tumoral Expression in Oral Cavity Squamous Cell Carcinoma
Singh, A., Nagarkar, N. M., Chowhan, A. K., Mehta, R., Arora, R. D., Rao, K. N., & Dange, P. (2024) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-024-01984-0 · Cited by 1
Talaat, S. M., William, H., Roby, N. M., & Keshk, E. M. S. (2024) · Research in Oncology · doi:10.21608/resoncol.2024.213776.1196 · Cited by 1
Development and Characterization of an Anti-PD-L1 Immunotoxin for Targeted Cancer Therapy
Takhteh, A., Hosseininejad-Chafi, M., Oghalaie, A., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010321088240823062243 · Cited by 1
Arai, M., Tanaka, N., Takamatsu, K., Murakami, T., Mikami, S., Imamura, T., Nakamura, K., Nishihara, H., & Oya, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04020-4 · Cited by 1
Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study
Liu, M., Bane, O., Mu, X., Al-Mubarak, H. F. I., Abboud, G., Reddy, A., Kennedy, P., Robson, P. M., Meilika, K., Zuluaga, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012833 · Cited by 1
Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression
Yeware, A. M., Brown, C., Chang, C.-C., Pennati, A., & Galipeau, J. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06208-y · Cited by 1
Jin, X., Yang, J., Miao, D., Xiong, W., & Xiong, Z. (2026) · Biomedicines · doi:10.3390/biomedicines14061181 · Cited by 1
Tanaka, Y., Morita, C. T., & Okamura, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_19 · Cited by 1
T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer
Ott, P. A., & Hodi, F. S. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_10 · Cited by 1
Basic Principles of Immunology in Urology
Flechner, S. M., Finke, J. H., & Fairchild, R. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00017-7 · Cited by 1
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.